Finished
Single-port Robotic Transanal Total Mesorectal Excision
NCT06591572 · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Updated 17 Sept 2025
- What is being tested
- Single-port robotic transanal total mesorectal excision
- For
- Rectal Cancer Patients
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years and older. About 20 people. The full rules are on the registry page.
- Where
- China
- When
- Starts or started 24 Oct 2024, ends 1 Sept 2025. Registered 19 Sept 2024.
- Results
- None posted yet.
In the researchers' words
This is a phase 2a clinical trial based on the IDEAL framework to evaluate the safety, feasibility and clinical efficacy of single-port robotic transanal total mesorectal excision (SPr-taTME )surgery. For safety, intraoperative adverse events and 30-day morbidity. For efficacy, successful completion of predefined procedural steps without conversion. The transanal surgical platform consists of a single-port robotic system, while the transabdominal approach can be performed laparoscopically or with single-port robotic assistance.
Sites
- Huichao ZhengChongqing, China